Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review.
COVID-19
SARS-CoV-2
immunosuppressants
intravenous immunoglobulins
polyclonal antibodies
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
09 Jan 2022
09 Jan 2022
Historique:
received:
08
12
2021
revised:
30
12
2021
accepted:
06
01
2022
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
23
1
2022
Statut:
epublish
Résumé
Although several therapeutic strategies have been investigated, the optimal treatment approach for patients with coronavirus disease (COVID-19) remains to be elucidated. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of polyclonal intravenous immunoglobulin (IVIG) therapy in COVID-19. A systematic literature search using appropriate medical subject heading (MeSH) terms was performed through Medline (PubMed), EMBASE, SCOPUS, OVID and Cochrane Library electronic databases. The main outcomes considered were mortality and safety of IVIG versus placebo/standard of care. This review was carried out in accordance with Cochrane methodology including the risk bias assessment and grading of the quality of evidence. Measures of treatment effect were mean differences (MD) together with 95% confidence intervals (CIs) for continuous outcome measures and risk ratio (RR) or MD for binary outcomes. Two reviewers independently extracted data from individual studies, and disagreements were resolved by a third reviewer. A total of 2401 COVID-19 patients from 10 studies (four randomized controlled trials (RCT) and six non-randomized controlled trials (non-RCTs)) were included in the analysis. Participants received IVIG or placebo/standard of care. The use of IVIG was not associated with a significantly reduced risk of death (RR 0.50, 95% CIs 0.18-1.36, The current evidence from the literature does not support the use of IVIG in COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although several therapeutic strategies have been investigated, the optimal treatment approach for patients with coronavirus disease (COVID-19) remains to be elucidated. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of polyclonal intravenous immunoglobulin (IVIG) therapy in COVID-19.
METHODS
METHODS
A systematic literature search using appropriate medical subject heading (MeSH) terms was performed through Medline (PubMed), EMBASE, SCOPUS, OVID and Cochrane Library electronic databases. The main outcomes considered were mortality and safety of IVIG versus placebo/standard of care. This review was carried out in accordance with Cochrane methodology including the risk bias assessment and grading of the quality of evidence. Measures of treatment effect were mean differences (MD) together with 95% confidence intervals (CIs) for continuous outcome measures and risk ratio (RR) or MD for binary outcomes. Two reviewers independently extracted data from individual studies, and disagreements were resolved by a third reviewer.
RESULTS
RESULTS
A total of 2401 COVID-19 patients from 10 studies (four randomized controlled trials (RCT) and six non-randomized controlled trials (non-RCTs)) were included in the analysis. Participants received IVIG or placebo/standard of care. The use of IVIG was not associated with a significantly reduced risk of death (RR 0.50, 95% CIs 0.18-1.36,
CONCLUSIONS
CONCLUSIONS
The current evidence from the literature does not support the use of IVIG in COVID-19 patients.
Identifiants
pubmed: 35062755
pii: vaccines10010094
doi: 10.3390/vaccines10010094
pmc: PMC8779789
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Int Immunopharmacol. 2021 Jan;90:107205
pubmed: 33214093
Infect Prev Pract. 2020 Sep;2(3):100061
pubmed: 34316558
Emerg Infect Dis. 2004 May;10(5):818-24
pubmed: 15200814
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283154
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Med Hypotheses. 2021 Jun;151:110592
pubmed: 33878626
Int J Infect Dis. 2021 Apr;105:525-531
pubmed: 33434674
BMJ. 2021 Sep 23;374:n2231
pubmed: 34556486
Int Immunopharmacol. 2021 Sep;98:107891
pubmed: 34153671
Front Immunol. 2020 Jul 14;11:1660
pubmed: 32760407
BMJ. 2008 May 3;336(7651):995-8
pubmed: 18456631
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Immunotherapy. 2020 Jun;12(8):571-576
pubmed: 32397847
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Front Immunol. 2021 Apr 28;12:675679
pubmed: 33995420
J Med Virol. 2021 May;93(5):2675-2682
pubmed: 33314173
Virol J. 2021 May 21;18(1):101
pubmed: 34020680
J Infect Dis. 2021 May 20;223(9):1538-1543
pubmed: 33585890
Int Immunopharmacol. 2021 Jul;96:107732
pubmed: 34162133
Pharmaceuticals (Basel). 2021 May 28;14(6):
pubmed: 34071185
Clin Microbiol Infect. 2021 Oct;27(10):1488-1493
pubmed: 34020032
Curr Med Res Opin. 2021 Apr;37(4):543-548
pubmed: 33236646
Crit Care Explor. 2020 Nov 16;2(11):e0280
pubmed: 33225306
Life (Basel). 2021 Apr 18;11(4):
pubmed: 33919577
Vox Sang. 2021 Oct;116(9):935-942
pubmed: 33794556
BMC Infect Dis. 2020 Oct 21;20(1):786
pubmed: 33087047
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33571169
Clin Transl Immunology. 2020 Oct 14;9(10):e1192
pubmed: 33082954